RWE

Deep 6 AI Expands Its Recruitment Acceleration Solution for Life Sciences to Shorten the Time from Determining Patient Eligibility to Enrollment

Retrieved on: 
Wednesday, December 6, 2023
Ethnic group, Name, IRB, Organization, Gene, RPD, EMR, Patient, Genomics, Marker beacon, Medicine, RWD, Ecosystem, Artificial intelligence, Conference, SCOPE, Physician, Life, Registry, RWE, Medical device, Nursing

PASADENA, Calif., Dec. 6, 2023 /PRNewswire/ -- Deep 6 AI, the leader in AI-powered precision research software which de-risks and accelerates clinical trials for research sites and sponsors, today announced the expansion of its Recruitment Acceleration solution, known for leveraging artificial intelligence (AI) to mine the industry's deepest source of real-time electronic medical record (EMR) data to precisely find patients for trials. With the expanded solution, life sciences companies can share AI-matched patient cohorts with IRB-approved site staff across the Deep 6 AI ecosystem. This allows sites to identify each patient, validate their eligibility with evidence in the EMR, and track their recruitment statuses faster and more precisely, shortening the time to enrollment.

Key Points: 
  • With the expanded solution, life sciences companies can share AI-matched patient cohorts with IRB-approved site staff across the Deep 6 AI ecosystem.
  • This allows sites to identify each patient, validate their eligibility with evidence in the EMR, and track their recruitment statuses faster and more precisely, shortening the time to enrollment.
  • Deep 6 AI also offers expanded access to all these precision-matched, trial-eligible patients, across all site locations and physicians.
  • Deep 6 AI's life sciences solutions also provide access to advanced genomics and diversity, equity, and inclusion (DE&I) insights.

Masdar Joins Forces with RWE in £11 billion Investment to Co-develop Massive 3GW Offshore Wind Projects in UK

Retrieved on: 
Friday, December 1, 2023
London Array, RWE, Coal, DBS, International Renewable Energy Agency, Dudgeon, UN, COP28, RWE AG, Investment, PJSC, Wind, Dogger Bank, Solar energy, Farm, Growth, Electricity, Temperature, Renewable energy, Drug, Masdar

The 3GW DBS projects bring together global clean energy pioneers Masdar and RWE, a leading renewable energy company headquartered in Germany.

Key Points: 
  • The 3GW DBS projects bring together global clean energy pioneers Masdar and RWE, a leading renewable energy company headquartered in Germany.
  • Today's investment in the 3GW DBS projects - almost five times as big as London Array - shows Masdar's steadfast expansion into the exciting offshore wind sector.
  • Masdar has also invested in the 30MW Hywind project, which was the world's first floating offshore wind farm, and the 402MW Dudgeon offshore wind farm.
  • RWE is already one of the leading companies in the field of renewable energy and offshore wind.

Masdar Joins Forces with RWE in £11 billion Investment to Co-develop Massive 3GW Offshore Wind Projects in UK

Retrieved on: 
Friday, December 1, 2023
London Array, RWE, Coal, DBS, International Renewable Energy Agency, Dudgeon, UN, COP28, RWE AG, Investment, PJSC, Wind, Dogger Bank, Solar energy, Farm, Growth, Electricity, Temperature, Renewable energy, Drug, Masdar

The 3GW DBS projects bring together global clean energy pioneers Masdar and RWE, a leading renewable energy company headquartered in Germany.

Key Points: 
  • The 3GW DBS projects bring together global clean energy pioneers Masdar and RWE, a leading renewable energy company headquartered in Germany.
  • Today's investment in the 3GW DBS projects - almost five times as big as London Array - shows Masdar's steadfast expansion into the exciting offshore wind sector.
  • Masdar has also invested in the 30MW Hywind project, which was the world's first floating offshore wind farm, and the 402MW Dudgeon offshore wind farm.
  • RWE is already one of the leading companies in the field of renewable energy and offshore wind.

ProPharma Launches an Integrated MedTech Organization Providing End-to-End Solutions for Innovators

Retrieved on: 
Thursday, November 16, 2023
Odyssey, Real-World Evidence, Data management, Safety, Digital therapeutics, Software, 2005 in television, MDR, Notified body, Companion, Medtech, LDT, U.S. FDA, Verification and validation, FDA, QMS, Medical device, Form FDA 483, Digital, Integrated Global System Model, Wearable computer, Geography, Development, RCO, Combination, SRL Diagnostics, Surveillance capitalism, Quality management, IVDR, Single-frequency network, RWE, Health technology, Pharmaceutical industry, Device

RALEIGH, N.C., Nov. 16, 2023 /PRNewswire-PRWeb/ -- ProPharma Group, the world's largest Research Consulting Organization (RCO) and the leading global provider of regulatory, clinical and quality compliance services for the life sciences industry, has today launched a new Integrated Global MedTech Practice to provide end-to-end solutions for medical technology companies.

Key Points: 
  • ProPharma Group has today launched a new Integrated Global MedTech Practice to provide end-to-end solutions for medical technology companies.
  • "ProPharma's new MedTech practice has extensive experience and offers scalable solutions tailored to client needs, regardless of size or geography" –Dr.
  • The MedTech organization includes Regulatory Strategy, Clinical Strategy and Development, Quality Management and Compliance, Market Access and Reimbursement, and Post Market Surveillance.
  • For more information about ProPharma Group's Global MedTech Practice and its suite of services, please visit https://www.propharmagroup.com/ .

Non-alcoholic steatohepatitis (NASH) real-world evidence innovation further extends Verantos' lead in artificial intelligence for cardiometabolic conditions

Retrieved on: 
Monday, November 13, 2023
RWE, Hepatology, PALO, NAFLD, Natural language processing, Organization, Prevalence, AASLD, DSM-IV codes, Patient, RWD, American Liver Foundation, Intelligence, Obesity, Non-alcoholic fatty liver disease, Chronic liver disease, NASH, Medical device

PALO ALTO, Calif., Nov. 13, 2023 /PRNewswire/ -- Verantos, the global leader in high-validity real-world evidence at scale, today announced the presentation of an abstract on the use of artificial intelligence in cardiometabolic conditions. The technology enables researchers to gather high-quality real-world data on NASH, non-alcoholic fatty liver disease (NAFLD), and related conditions.

Key Points: 
  • PALO ALTO, Calif., Nov. 13, 2023 /PRNewswire/ -- Verantos , the global leader in high-validity real-world evidence at scale, today announced the presentation of an abstract on the use of artificial intelligence in cardiometabolic conditions.
  • The technology enables researchers to gather high-quality real-world data on NASH, non-alcoholic fatty liver disease (NAFLD), and related conditions.
  • "Verantos' advances in artificial intelligence afford life sciences organizations unprecedented real-world insights into metabolic diseases," said Dan Riskin, M.D., CEO of Verantos.
  • The number of cases is growing with the increasing prevalence of obesity and type 2 diabetes.

TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options

Retrieved on: 
Monday, November 13, 2023
Calibration, Hepatology, Research, Entrepreneurship, AASLD, Liver disease, Fatty liver disease, Patient, Metabolism, Liver, Cirrhosis, PRO, MASH, American Heart, Target, Public, RWE, American Heart Association, Dietary supplement, Medical imaging, Pharmaceutical industry, Boston

DURHAM, N.C., Nov. 13, 2023 /PRNewswire/ -- In response to the growing unmet need for real-world evidence (RWE) surrounding metabolic liver diseases, industry leader Target RWE released new updates on TARGET-NASH, one of the largest real-world datasets of its kind.

Key Points: 
  • 15% have been treated or are currently being treated with a GLP-1 receptor agonist.
  • The TARGET-NASH longitudinal registry has enrolled more than 7,000 patients in the U.S. and Europe, with approximately 750 pediatric patients.
  • "Metabolic liver diseases are some of the most concerning public health concerns facing populations around the world.
  • Until now, stakeholders had little access to treatment patterns for this complex patient population being treated for multiple co-morbidities."

World Healthcare Data Research Report 2023: Market to Triple by 2030 - New Entrants and Incumbents are Leveraging RWD/RWE to Generate Valuable Insights

Retrieved on: 
Monday, November 13, 2023
Real-World Evidence, Drug development, Acquisition, Real, Organization, Health policy, Real world evidence, Electronic health record, RWD, Public health surveillance, Ecosystem, Health information management, Procurement, COVID-19, Flatiron, Evidence, RWE, Research report, Pharmaceutical industry, Sales, Research

The report provides valuable insights into the current and future state of the RWD/RWE market.

Key Points: 
  • The report provides valuable insights into the current and future state of the RWD/RWE market.
  • These trends are leading to a rapidly growing market, which this report forecasts will experience an average 14.6% CAGR through 2030, roughly tripling today's addressable market from $4.6B to $13.6B USD.
  • The research is relevant to any healthcare stakeholder looking to leverage real-world data for evidence-based decision making.
  • The mass digitization of healthcare records over the past decade has led to an explosion of new, highly-valued clinical data assets.

Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases

Retrieved on: 
Friday, November 10, 2023
MSHS, Calibration, Disease, Hepatology, Safety, Prevalence, Entrepreneurship, AASLD, CQC, Liver disease, Mortality, Chief Medical Officer (Ireland), Fatty liver disease, Patient, Liver, Cirrhosis, TARGET, Chronic liver disease, Partnership, Quality of life, LD, American Heart, RWE, American Heart Association, Pharmaceutical industry, Boston

DURHAM, N.C., Nov. 10, 2023 /PRNewswire/ -- Real-world evidence (RWE) leader Target RWE announced today that the CQC and TARGET-Liver Disease (LD) partnership with the American Association for the Study of Liver Diseases (AASLD) has enrolled approximately 75,000 patients.

Key Points: 
  • DURHAM, N.C., Nov. 10, 2023 /PRNewswire/ -- Real-world evidence (RWE) leader Target RWE announced today that the CQC and TARGET-Liver Disease (LD) partnership with the American Association for the Study of Liver Diseases (AASLD) has enrolled approximately 75,000 patients.
  • Target RWE has enrolled approximately 75,000+ patients under the TARGET-LD protocol to support AASLD/CQC.
  • The strategic partnership between Target RWE and AASLD is designed to fulfill the unmet need for a large, real-world registry of patients with chronic liver diseases.
  • "These liver diseases are growing in prevalence and are placing a tremendous burden on healthcare systems around the world.

Folia Health Announces Groundbreaking Flare Tracking Technology to Bridge Research Gaps and Enhance Chronic Condition Management

Retrieved on: 
Thursday, November 9, 2023
Patient, Health care, MPH, NIH Intramural Research Program, Real world evidence, Sickle cell disease, Real world data, Conditional sentence, Health, Quality of life, Research, RWE, Real, Predictive analytics, Algorithm, Nursing, Pharmaceutical industry, Flare

Folia Health's Flare Tracking Technology provides an innovative solution that reimagines the horizon of acute event management, improving patient care and contributing to vital research endeavors.

Key Points: 
  • Folia Health's Flare Tracking Technology provides an innovative solution that reimagines the horizon of acute event management, improving patient care and contributing to vital research endeavors.
  • 3) Bridging Research Gaps: By analyzing Flare data between clinic visits, Folia Health's technology contributes to the wealth of Real World Evidence (RWE), improving our understanding of chronic diseases and refining treatment strategies.
  • Nell Meosky Luo, Chief Executive Officer and Founder at Folia Health, commented, “Our Flare Tracking Technology represents a significant step forward in the understanding of chronic diseases.
  • To learn more about Folia Health's Flare Tracking Technology and its dual impact on chronic disease management and research, please visit https://www.foliahealth.com/research or reach out to [email protected] .

World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

Retrieved on: 
Thursday, November 9, 2023
Knowledge, Post-traumatic stress disorder, University of Calgary, MDMA, Veterans Affairs Canada, UC, Physician, OTC, Health Canada, Ethics, Special access program, Party, Research, RWE, CSE, Trauma, Nature, PTSD, Trial, Real, Clinical trial, Partnership, SAP, University, LOI, GMP, Safety, Collection, Patient, DSM-IV codes, Mental health, Senate, Pharmaceutical industry, Veteran

The University of Calgary, under the direction of Dr. Leah Mayo, Parker Research Chair in Psychedelics, will assess data pertaining to efficacy of MDMA in the treatment of PTSD under real-world circumstances.

Key Points: 
  • The University of Calgary, under the direction of Dr. Leah Mayo, Parker Research Chair in Psychedelics, will assess data pertaining to efficacy of MDMA in the treatment of PTSD under real-world circumstances.
  • This trial will generate Real World Evidence (“RWE”) on the efficacy of MDMA in the treatment of Post-Traumatic Stress Disorder which may be submitted to Health regulators, including Health Canada and Veterans Affairs Canada.
  • As the trial is Observational in nature, no patients will be dosed as part of the trial’s protocol.
  • The goal of the trial is to gather data on the efficacy of treatment for patients who are already qualified for treatment under the Special Access Program.